在过去的 30 年里，将单克隆抗体 (mAb) 治疗纳入血液恶性肿瘤的治疗中已经显着改善了患者的治疗效果。 mAb 治疗的主要限制是需要在主要组织相容性复合物 (MHC) 和共刺激分子上呈递靶抗原，以引发细胞毒性免疫反应。随着双特异性抗体 (BsAb) 的出现，可以通过直接刺激细胞毒性 T 细胞来克服这些限制，从而限制肿瘤细胞的逃避。 BsAb 正在迅速被纳入血液系统恶性肿瘤的治疗方案中，目前 FDA 已批准了 7 种此类治疗方法，其中 6 种已于去年获得批准。在这篇综述中，我们描述了 CD3 BsAb 在治疗淋巴瘤、骨髓瘤和白血病中的功能、并发症和临床试验数据。版权所有 © 2024 Elsevier Inc. 保留所有权利。

Over the past 30 years the incorporation of monoclonal antibody (mAb) treatments into the management of hematologic malignancies has led to significant improvements in patient outcomes. The key limitation of mAb treatments is the necessity for target antigen presentation on major histocompatibility complex (MHC) and costimulatory molecules to elicit a cytotoxic immune response. With the advent of bispecific antibodies (BsAbs), these limitations can be overcome through direct stimulation of cytotoxic T cells, thus limiting tumor cell evasion. BsAbs are rapidly being incorporated into treatment regimens for hematologic malignancies, and there are now seven FDA-approved treatments in this class, six of which have been approved in the past year. In this review we describe the function, complications, and clinical trial data available for CD3 BsAbs in the treatment of lymphoma, myeloma, and leukemia.Copyright © 2024 Elsevier Inc. All rights reserved.